Kadcyla binds to the HER2 receptors on the surface of cancer cells. Once attached, it is internalized into the cell, where the emtansine component is released. Emtansine then disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis (programmed cell death). This mechanism allows for a more precise and effective treatment of HER2-positive cancers.
